SCHEMBL23828282

SCHEMBL23828282

Cc1ccc2[nH]c3c(c2c1)CN(C(=O)c1ccco1)CC3

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 6/20 0.79
▸ BAZ2B Q9UIF8 2/20 0.67
▸ LMNA P02545 2/20 0.62
▸ PABPC1 P11940 1/20 0.62
▸ ATM Q13315 1/20 0.62
▸ SMN1; SMN2 Q16637 1/20 0.62
▸ ALDH1A1 P00352 10/20 0.60
▸ MAPT P10636 7/20 0.60
▸ MEN1 O00255 5/20 0.60
▸ KMT2A Q03164 5/20 0.60
▸ NPC1 O15118 1/20 0.58
▸ CFTR P13569 2/20 0.57
▸ CASP1 P29466 4/20 0.56
▸ CASP7 P55210 3/20 0.56
▸ USP2 O75604 2/20 0.56
▸ KDM4E B2RXH2 3/20 0.55
▸ HPGD P15428 3/20 0.55
▸ TDP1 Q9NUW8 3/20 0.55
▸ HTT P42858 2/20 0.55
▸ POLB P06746 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23828288 0.83 BAZ2B (0.64) GAABAZ2BLMNAPABPC1ATM
SCHEMBL30570544 0.83 BAZ2B (0.64) GAABAZ2BLMNAPABPC1ATM
SCHEMBL31117415 0.82 BAZ2B (0.72) GAABAZ2BLMNAPABPC1ATM
SCHEMBL23828230 0.82 CFTR (0.77) GAABAZ2BLMNAPABPC1ATM
SCHEMBL30570546 0.82 CFTR (0.77) GAABAZ2BLMNAPABPC1ATM
SCHEMBL3424575 0.81 BAZ2B (0.81) GAABAZ2BLMNAPABPC1ATM
SCHEMBL12868355 0.81 BAZ2B (1.00) GAABAZ2BLMNAPABPC1ATM
SCHEMBL23828296 0.80 CFTR (0.64) GAABAZ2BLMNAPABPC1ATM
SCHEMBL23828213 0.78 BAZ2B (0.65) GAABAZ2BLMNAPABPC1ATM
SCHEMBL31020960 0.78 BAZ2B (0.65) GAABAZ2BLMNAPABPC1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820867-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS FONDAZIONE ST ITALIANO TECNOLOGIA (IT) 2023-09-13 — — EP claimed
US-20210292324-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2021-09-23 — — US claimed
US-11999734-B2 Compounds and compositions for the treatment of cystic fibrosis FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2024-06-04 — — US disclosed
EP-3820867-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS FONDAZIONE ST ITALIANO TECNOLOGIA (IT) 2023-09-13 — — EP disclosed
US-20210292324-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2021-09-23 — — US disclosed
US-20210292324-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2021-09-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999734-B2 Compounds and compositions for the treatment of cystic fibrosis CFTR, ABCB11, ABCC5 GAA 660/4885BAZ2B 4498/4885LMNA 2957/4885
US-20210292324-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCB11, ABCC5 GAA 660/4885BAZ2B 4498/4885LMNA 2957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback